CompletedPhase 3NCT00979745
Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Studying Autosomal erythropoietic protoporphyria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Clinuvel Pharmaceuticals Limited
- Principal Investigator
- Alex Anstey, MBBS, FRCPSt Woolos Hospital, Newport
- Intervention
- Afamelanotide(drug)
- Enrollment
- 74 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2009 – 2011
Study locations (8)
- HUS:n Iho-ja allergiasairaala (Skin and Allergy Hospital), Helsinki, Finland
- Centre Français des Porphyries, Hôpital Louis Mourier, Colombes, Cedex, France
- Department of Dermatology , Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
- Beaumont Hospital, Department of Dermatology, Dublin, Ireland
- Academisch Ziekenhuis Maastricht, Maastricht, Netherlands
- Erasmus Medical Center, Rotterdam, Netherlands
- St Woolos Hospital, Newport, Wales, United Kingdom
- Photobiology Unit - Hope Hospital, University of Manchester, Manchester, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00979745 on ClinicalTrials.govOther trials for Autosomal erythropoietic protoporphyria
Additional recruiting or active studies for the same condition.
See all trials for Autosomal erythropoietic protoporphyria →